Clinical Trials

Phase II trial to evaluate synthetic epothilone for cancer treatment

Published in Women's Health Weekly, December 29th, 2005

Schering AG, Germany (SCH, SHR) announced the start of three phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer.

The clinical trials will assess ZK-EPO's safety and efficacy in each of these cancer types.

ZK-EPO is the only fully synthetic epothilone in clinical development. It is designed to improve efficacy and safety compared to the chemotherapies currently available.

In non-small cell lung cancer, a multicenter study is currently enrolling patients in Germany. The trial is designed to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-12-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry